CDK 4 and 6 Inhibitors in HR-Positive Advanced Breast Cancer: Assessing New Data.

Slides:

Advertisements

Similar presentations

Results of a Randomized Phase 2 Study of PD , a Cyclin ‐ Dependent Kinase (CDK) 4/6 Inhibitor, in Combination with Letrozole vs Letrozole Alone.

Advertisements

PHASE II RANDOMIZED STUDY OF TRASTUZUMAB EMTANSINE VERSUS TRASTUZUMAB PLUS DOCETAXEL IN PATIENTS WITH HUMAN EPIDERMAL GROWTH FACTOR RECEPTOR 2 – POSITIVE.

MONARCH 2: Phase III Study of Abemaciclib + Fulvestrant in HR+/HER2- Advanced Breast Cancer After Progression on Endocrine Therapy CCO Independent Conference.

CCO Independent Conference Coverage

CDK 4 and 6 Inhibitors in HR-Positive Advanced Breast Cancer: Assessing New Data.

PALOMA-2: Addition of Palbociclib to Frontline Letrozole Significantly Improves PFS in Postmenopausal ER+/HER2- Advanced Breast Cancer CCO Independent.

Bladder Cancer: A New Era in Treatment

This program will include a discussion of off-label treatment and investigational agents not approved by the FDA for use in the US, and data that were.

Vahdat L et al. Proc SABCS 2012;Abstract P

Individualizing Treatment Options in Advanced ER-Positive Breast Cancer.

Optimizing Combination Endocrine Therapy in HR-Positive Advanced Breast Cancer.

Presented By Luca Malorni at 2017 ASCO Annual Meeting

Endocrine Combinations in HR-Positive MBC: The Future Is Now

The Use of PARP Inhibitors in Breast Cancer: Challenges and Opportunities.

Evolving Paradigms in the Management of HR-Positive Breast Cancer

CDK 4 and 6 Inhibitors in HR-Positive Breast Cancer: Implementing Paradigms in Clinical Practice.

The Nurse View: Hormone Receptor-Positive Advanced Breast Cancer

Expanding Horizons in the Clinical Care of ER-Positive, HER2-Negative Metastatic Breast Cancer.

Updates on the Use of Adjuvant Therapy in HER2-Positive Breast Cancer

New Horizons in the Management of Advanced Breast Cancer

CDK 4 and 6 Inhibitors in HR-Positive Breast Cancer: A Clinical Update

Her2-positive breast cancer: updating current best practice

Glaucoma Progression.

Essential Concepts in Harnessing the Immune System in Head and Neck Cancer.

سرطان الثدي Breast Cancer

Overall Program Goals. Overall Program Goals Current Approaches.

Metastatic Renal Cell Carcinoma

Individualizing Treatment Options in Advanced ER-Positive Breast Cancer.

Program Goals. Targeting New Pathways for Overcoming Endocrine Resistance in Breast Cancer.

PARP and Other DNA Damage Repair Inhibitors in Solid Tumors: An Update

Navigating New Treatment Landscapes in HR-Positive, HER2-Negative Metastatic Breast Cancer.

Moving Evidence into Practice: Breast Cancer Highlights From Chicago

Differentiating Among the CDK 4/6 Inhibitors in the Management of Metastatic Breast Cancer.

CDK4/6 Inhibitors in Breast Cancer:

Novel and Emerging Approaches to Treating CLL

CDK4/6 Inhibitors in Practice

Managing gBRCA-Positive Metastatic Breast Cancer

Using CDK4/6 Inhibitors to Manage HR-Positive Metastatic Breast Cancer

Treatment of HR+ Breast Cancer: A Clinical Update

Presented By Johanna Bendell at 2016 ASCO Annual Meeting

Reviewer: Dr. Sunil Verma Date posted: December 12th, 2011

Hormone Receptor-Positive Advanced Breast Cancer:

Baselga J et al. SABCS 2009;Abstract 45.

Using Heart Rate as a Biomarker in Clinical Practice.

CDK4/6 Biomarkers: Issues and Opportunities

Maintenance Therapy in Advanced Ovarian Cancer

The Road to Quality Improvement in HER2-Positive Breast Cancer

PARP Inhibitors.

Hormone Receptor-Positive Advanced Breast Cancer Introduction

Introduction Advanced Hormone Receptor-Positive Breast Cancer

Treatment of Locally Advanced Pancreatic Cancer

Managing Patients with Relapsed CLL who Discontinue BCR Signaling Inhibitors.

This program will include a discussion of off-label treatment and investigational agents not approved by the FDA for use in the US, and data that were.

New Paradigms in HR-Positive Advanced Breast Cancer

Optimizing Treatment in HR-Positive Breast Cancer: A Case-Based Discussion.

CDK 4/6 Inhibitors in Breast Cancer

FDA-Approved PI3K Inhibitors for CLL and FL

Martin M et al. Proc SABCS 2012;Abstract S1-7.

Preparing for Checkpoint Inhibitors in Breast Cancer

CDK4/6 Biomarkers: Issues and Opportunities

Navigating New Treatment Landscapes in HR+ HER2-Negative Advanced Breast Cancer.

Optimizing Front-Line Endocrine Therapy in Metastatic Breast Cancer

Clinical Considerations in the Use of Checkpoint Inhibitors Breast Cancer.

CDK4/6 Inhibitors.

Real-World Evidence.

This program will include a discussion of off-label treatment and investigational agents not approved by the FDA for use in the US, and data that were.

Clinical Pearls in the Management of Patients With Advanced Non-Small Cell Lung Cancer.

Clinical Focus.

Identifying TRK Fusions in Head and Neck Cancer

Miquel Àngel Seguí Palmer ¿Ciclinas para todas?

Presentation transcript:

CDK 4 and 6 Inhibitors in HR-Positive Advanced Breast Cancer: Assessing New Data

Program Overview

Should Clinicians Consider a CDK 4 and 6 Inhibitor in Combination With ET as Upfront Strategy?

Assessing the New Data

PALOMA-1: Phase 2 Study Design

PALOMA-1: Overall Survival

Is PFS Important Enough for Considering Palbociclib in Clinical Practice?

MONALESSA-2: Study Design

MONALEESA-2: PFS Update

MONALEESA-2 Health-Related Quality of Life

MONARCH-2: Study Design

MONARCH-2: PFS (ITT)

PALOMA-3 and MONARCH-2 Characteristics

MONARCH-2: ORR

MONARCH-2: Incidence of Grade 2/3 Diarrhea

Cumulative Incidence of All-Casualty AEs >15% During the First 5 Years of Palbociclib Treatment (N=83)

Managing Neutropenia Associated With CDK 4 and 6 Inhibitors

When Patients Progress After Treatment With CDK 4 and 6 Inhibitors: Unanswered Questions

Assessing Biomarker Data

Take Home Messages

Take Home Messages (cont)

CDK 4 and 6 Inhibitors in HR-Positive Advanced Breast Cancer: Assessing New Data

Abbreviations (cont)

Abbreviations (cont)